Strategies for extended serum half-life of protein therapeutics.
暂无分享,去创建一个
[1] J. Bading,et al. Biodistribution and tumor imaging of an anti-CEA single-chain antibody-albumin fusion protein. , 2008, Nuclear medicine and biology.
[2] B. Bacon,et al. Albinterferon Alfa-2b was not inferior to pegylated interferon-α in a randomized trial of patients with chronic hepatitis C virus genotype 1. , 2010, Gastroenterology.
[3] S. Schulte,et al. Half-life extension through albumin fusion technologies. , 2009, Thrombosis research.
[4] Lucy J. Holt,et al. Anti-serum albumin domain antibodies for extending the half-lives of short lived drugs. , 2008, Protein engineering, design & selection : PEDS.
[5] Tetsu Kobayashi,et al. Importance of Neonatal FcR in Regulating the Serum Half-Life of Therapeutic Proteins Containing the Fc Domain of Human IgG1: A Comparative Study of the Affinity of Monoclonal Antibodies and Fc-Fusion Proteins to Human Neonatal FcR , 2010, The Journal of Immunology.
[6] Kirstin A. Zettlitz,et al. The effects of affinity and valency of an albumin-binding domain (ABD) on the half-life of a single-chain diabody-ABD fusion protein. , 2010, Protein engineering, design & selection : PEDS.
[7] Charles L Brooks,et al. Albumin binding to FcRn: distinct from the FcRn-IgG interaction. , 2006, Biochemistry.
[8] Yik Andy Yeung,et al. A therapeutic anti-VEGF antibody with increased potency independent of pharmacokinetic half-life. , 2010, Cancer research.
[9] Felix Kratz,et al. Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles. , 2008, Journal of controlled release : official journal of the Controlled Release Society.
[10] Simona Jevševar,et al. PEGylation of therapeutic proteins , 2010, Biotechnology journal.
[11] R. Kontermann,et al. Bispecific Antibodies for Cancer Immunotherapy , 2010, BioDrugs.
[12] R. Kontermann,et al. N-Glycosylation as Novel Strategy to Improve Pharmacokinetic Properties of Bispecific Single-chain Diabodies* , 2008, Journal of Biological Chemistry.
[13] Jos H. Beijnen,et al. Clinical Pharmacokinetics of Therapeutic Monoclonal Antibodies , 2010, Clinical pharmacokinetics.
[14] R. Kontermann,et al. Improved Pharmacokinetics of Recombinant Bispecific Antibody Molecules by Fusion to Human Serum Albumin* , 2007, Journal of Biological Chemistry.
[15] J. Sturis,et al. Insulin detemir is a fully efficacious, low affinity agonist at the insulin receptor , 2010, Diabetes, obesity & metabolism.
[16] Leslie R Evans,et al. The production, characterisation and enhanced pharmacokinetics of scFv-albumin fusions expressed in Saccharomyces cerevisiae. , 2010, Protein expression and purification.
[17] M. Otagiri,et al. Pharmaceutical Strategies Utilizing Recombinant Human Serum Albumin , 2002, Pharmaceutical Research.
[18] V. Gaberc-Porekar,et al. Obstacles and pitfalls in the PEGylation of therapeutic proteins. , 2008, Current opinion in drug discovery & development.
[19] F. Salazar,et al. Tuning the serum persistence of human serum albumin domain III:diabody fusion proteins. , 2010, Protein engineering, design & selection : PEDS.
[20] G. Gregoriadis,et al. Development and Testing of Solid Dose Formulations Containing Polysialic Acid Insulin Conjugate: Next Generation of Long-Acting Insulin , 2010, Journal of diabetes science and technology.
[21] Christof Baltes,et al. A portable albumin binder from a DNA-encoded chemical library. , 2008, Angewandte Chemie.
[22] G. A. Lazar,et al. Enhanced antibody half-life improves in vivo activity , 2010, Nature Biotechnology.
[23] R. J. Solá,et al. Glycosylation of Therapeutic Proteins , 2010, BioDrugs.
[24] D. Lauffenburger,et al. Rational cytokine design for increased lifetime and enhanced potency using pH-activated “histidine switching” , 2002, Nature Biotechnology.
[25] G. Gregoriadis,et al. Improving the therapeutic efficacy of peptides and proteins: a role for polysialic acids. , 2005, International journal of pharmaceutics.
[26] Eetu Mäkelä,et al. Nephrin strands contribute to a porous slit diaphragm scaffold as revealed by electron tomography. , 2004, The Journal of clinical investigation.
[27] V. Rustgi. Albinterferon alfa-2b, a novel fusion protein of human albumin and human interferon alfa-2b, for chronic hepatitis C , 2009, Current medical research and opinion.
[28] Chichi Huang,et al. Receptor-Fc fusion therapeutics, traps, and MIMETIBODY technology. , 2009, Current opinion in biotechnology.
[29] F. Fares,et al. Development of a long-acting erythropoietin by fusing the carboxyl-terminal peptide of human chorionic gonadotropin beta-subunit to the coding sequence of human erythropoietin. , 2007, Endocrinology.
[30] R. Kontermann,et al. Biodistribution of a Bispecific Single-chain Diabody and Its Half-life Extended Derivatives* , 2009, The Journal of Biological Chemistry.
[31] F. Veronese,et al. The Impact of PEGylation on Biological Therapies , 2012, BioDrugs.
[32] B. Haraldsson,et al. Why do we not all have proteinuria? An update of our current understanding of the glomerular barrier. , 2004, News in physiological sciences : an international journal of physiology produced jointly by the International Union of Physiological Sciences and the American Physiological Society.
[33] C Simone Fishburn,et al. The pharmacology of PEGylation: balancing PD with PK to generate novel therapeutics. , 2008, Journal of pharmaceutical sciences.
[34] S. Akilesh,et al. FcRn: the neonatal Fc receptor comes of age , 2007, Nature Reviews Immunology.
[35] T. Weimer,et al. Genetic fusion to albumin improves the pharmacokinetic properties of factor IX , 2009, Thrombosis and Haemostasis.
[36] Willem P C Stemmer,et al. A recombinant polypeptide extends the in vivo half-life of peptides and proteins in a tunable manner , 2009, Nature Biotechnology.
[37] C. R. Leemans,et al. Improved tumor targeting of anti–epidermal growth factor receptor Nanobodies through albumin binding: taking advantage of modular Nanobody technology , 2008, Molecular Cancer Therapeutics.
[38] R. Kontermann,et al. A novel tri-functional antibody fusion protein with improved pharmacokinetic properties generated by fusing a bispecific single-chain diabody with an albumin-binding domain from streptococcal protein G. , 2007, Protein engineering, design & selection : PEDS.
[39] R. Kontermann. Strategies to Extend Plasma Half-Lives of Recombinant Antibodies , 2012, BioDrugs.
[40] A. Velázquez,et al. Starch and albumin mixture as replacement fluid in therapeutic plasma exchange is safe and effective , 2008, Journal of clinical apheresis.
[41] A. Bar-Ilan,et al. Designing a long-acting human growth hormone (hGH) by fusing the carboxyl-terminal peptide of human chorionic gonadotropin beta-subunit to the coding sequence of hGH. , 2010, Endocrinology.
[42] Alessandra Villa,et al. New strategy for the extension of the serum half-life of antibody fragments. , 2009, Bioconjugate chemistry.
[43] Bert J Lao,et al. Improving Therapeutic Properties of Protein Drugs through Alteration of Intracellular Trafficking Pathways , 2008, Biotechnology progress.
[44] M. Scholle,et al. Gcg-XTEN: An Improved Glucagon Capable of Preventing Hypoglycemia without Increasing Baseline Blood Glucose , 2010, PloS one.
[45] V. Tesar,et al. Discovery and basic pharmacology of erythropoiesis-stimulating agents (ESAs), including the hyperglycosylated ESA, darbepoetin alfa: an update of the rationale and clinical impact , 2010, European Journal of Clinical Pharmacology.
[46] Lucy J. Holt,et al. Anti-serum albumin domain antibodies in the development of highly potent, efficacious and long-acting interferon. , 2010, Protein engineering, design & selection : PEDS.
[47] Kunihiro Hattori,et al. Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization , 2010, Nature Biotechnology.
[48] B. Liu,et al. An Albumin-Conjugated Peptide Exhibits Potent Anti-HIV Activity and Long In Vivo Half-Life , 2009, Antimicrobial Agents and Chemotherapy.
[49] Gary Walsh,et al. Biopharmaceutical benchmarks 2010 , 2010, Nature Biotechnology.
[50] K. Chester,et al. Site-specific polysialylation of an antitumor single-chain Fv fragment. , 2009, Bioconjugate chemistry.
[51] K. Tryggvason,et al. How does the kidney filter plasma? , 2005, Physiology.
[52] A. Verkleij,et al. Efficient inhibition of EGFR signalling and of tumour growth by antagonistic anti-EGFR Nanobodies , 2007, Cancer Immunology, Immunotherapy.
[53] J. Andersen,et al. Extending Half-life by Indirect Targeting of the Neonatal Fc Receptor (FcRn) Using a Minimal Albumin Binding Domain* , 2010, The Journal of Biological Chemistry.
[54] Marina Etcheverrigaray,et al. Highly glycosylated human alpha interferon: An insight into a new therapeutic candidate. , 2010, Journal of biotechnology.
[55] Mire Zloh,et al. Disulfide bridge based PEGylation of proteins. , 2008, Advanced drug delivery reviews.
[56] M. Tabrizi,et al. Elimination mechanisms of therapeutic monoclonal antibodies. , 2006, Drug discovery today.
[57] B. Meibohm,et al. Pharmacokinetic aspects of biotechnology products. , 2004, Journal of pharmaceutical sciences.